论文部分内容阅读
将10例血糖控制差的肥胖2型糖尿病患者,在使用二甲双胍+人胰岛素30R降糖基础上加用利拉鲁肽0.6mg ih qd,根据血糖水平调整人胰岛素30R的用量,直至血糖达标。分别记录治疗前(0个月)的及治疗后(2个月)的空腹血糖(FBG),餐后2小时血糖(PBG),空腹胰岛素(FINS),体重指数(BMI),血脂,并记录治疗前后局部反应和低血糖事件的发生。结果加用利拉鲁肽后,空腹血糖、糖化血红蛋白、ISI及外源性胰岛素用量明显下降,P<0.05,血脂有所改善,但无统计学意义。结论利拉鲁肽具有强大的促进胰岛素分泌的作用,可以减少外源性胰岛素的用量。同时可以减轻体重和血脂,减轻胰岛素抵抗,具有降糖以外的心血管保护作用。
10 patients with poorly controlled glycemic type 2 diabetes mellitus were treated with 0.6 mg ih qd of liraglutide based on the 30R glucose lowering effect of metformin plus human insulin, and the dosage of human insulin 30R was adjusted according to the blood glucose level until the blood glucose reached the standard. The fasting blood glucose (FBG), postprandial blood glucose (PBG), fasting insulin (FINS), body mass index (BMI) and blood lipids before treatment (0 months) and after treatment Local reactions before and after treatment and hypoglycaemic events. Results With the addition of liraglutide, fasting blood glucose, glycosylated hemoglobin, ISI and exogenous insulin decreased significantly, P <0.05, but lipid levels improved but not statistically significant. Conclusion Liraglutide has a strong role in promoting insulin secretion, can reduce the amount of exogenous insulin. At the same time can reduce body weight and blood lipids, reduce insulin resistance, with hypoglycemic cardiovascular protection.